New Polycythemia Vera Research: Inside the Divesiran Clinical Trial with Silence Therapeutics

Research into polycythemia vera (PV) continues to advance, and new therapeutic approaches are being explored to improve treatment options for patients living with myeloproliferative neoplasms (MPNs).

As part of the educational collaboration between the Global MPN Scientific Foundation and Silence Therapeutics, a new webinar will explore current research developments in the United States, including the progress of the divesiran clinical program.

This third session of the webinar series brings together experts from Silence Therapeutics who will share insights about the company’s research strategy, clinical development programs and collaboration with the patient community.

📅 Webinar information

📆 Date: Monday, March 26, 2026

🕘 Time: 6:00PM CET

💻 Online | English and Spanish simultaneous interpretation

🎤 Speaker: Dr. Curtis Rambaran, Chief Medical Officer, Silence Therapeutics

🎤 Speaker: Joe Loiars, Senior Director Medical Science Liaison, Silence Therapeutics USA

🤝 Organized by: Global MPN Scientific Foundation

Understanding the research behind new therapies for Polycythemia Vera.

During the webinar, Dr. Curtis Rambaran will introduce the structure and research strategy of Silence Therapeutics and explain how the company is developing innovative therapies targeting diseases such as polycythemia vera.

A key focus will be the divesiran program, an investigational therapy designed to regulate iron metabolism by increasing levels of hepcidin, a hormone that controls iron balance in the body. This approach may help reduce the excessive production of red blood cells that characterizes PV.

The therapy is currently being studied in the SANRECO Phase 2 clinical trial, which evaluates whether divesiran may help patients maintain hematocrit levels below 45 percent without the need for frequent phlebotomies.

In the second part of the webinar, Joe Loiars will provide an overview of Silence Therapeutics’ activities in the United States, including the current Phase 2 clinical study approach, research sites participating in the trial and the company’s collaboration with patient organizations.

He will also share highlights from major scientific meetings such as ASH 2025, as well as the importance of strengthening relationships between research teams, healthcare professionals and the patient community.

These conversations help patients better understand how new therapies are developed and how clinical trials contribute to advancing treatment options for MPN patients worldwide.

This session offers a unique opportunity to learn more about new research in polycythemia vera, ongoing clinical trials and future treatment possibilities.

Patients, caregivers and healthcare professionals are invited to join this conversation and explore the progress being made in the field of MPN research.

✨ Register here to participate in the webinar

If you would like to continue learning and connecting with others living with MPN, we invite you to explore the initiatives of the Global MPN Scientific Foundation.

📰 Subscribe to our newsletter to receive updates about research, webinars and community.

📝 Register for MPN JournalTrack your symptoms and treatment experience while contributing anonymously to a better understanding of life with MPN.

🌿 Explore the MPN Wellbeing ProjectA program designed to support quality of life through complementary practices that may help address symptoms and treatment side effects.

💬 Join our international WhatsApp patient groupsConnect with people living with MPN around the world and share experiences in a supportive community.

❤️ Support the Global MPN Scientific Foundation, Donations help expand education programs, international collaborations, and patient resources worldwide.

Together we continue building a stronger global network for people living with myeloproliferative neoplasms.